Payment overview · 2025
General Payments
$540.57
25 reported records · 3 companies
Healthcare provider profile · identity verified
Ajay Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT ALBANS, WV · NPI 1023078912
Verified facts
What the public records show
CMS Open Payments records show Ajay Patel, M.D. received $540.57 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 65.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $352.25 | 65.2% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $174.35 | 32.2% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.97 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $540.57 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $174.35 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $142.35 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $113.28 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $96.62 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 69 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 390 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 353 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 301 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 271 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 225 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 213 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 202 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 199 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 49 |
| Montelukast Sodium | Montelukast Sodium | 178 | 51 |
| Ezetimibe | Ezetimibe | 152 | 36 |
| Lisinopril | Lisinopril | 139 | 33 |
| Alprazolam | Alprazolam | 128 | 14 |
| Jardiance | Empagliflozin | 124 | 33 |
| Gabapentin | Gabapentin | 120 | 25 |
| Metformin Hcl Er | Metformin Hcl | 110 | 30 |
| Losartan Potassium | Losartan Potassium | 107 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 22 |
| Furosemide | Furosemide | 97 | 27 |
| Omeprazole | Omeprazole | 95 | 24 |
| Fenofibrate | Fenofibrate | 90 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 17 |
| Alendronate Sodium | Alendronate Sodium | 76 | 19 |
| Famotidine | Famotidine | 73 | 24 |
| Eliquis | Apixaban | 69 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 53 |
| Sertraline Hcl | Sertraline Hcl | 61 | 15 |
| Carvedilol | Carvedilol | 60 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 58 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 18 |
| Trazodone Hcl | Trazodone Hcl | 53 | 19 |
| Clonidine Hcl | Clonidine Hcl | 50 | 15 |
| Metformin Hcl | Metformin Hcl | 50 | 15 |
| Donepezil Hcl | Donepezil Hcl | 46 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 11 |
| Clonidine | Clonidine | 41 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Meloxicam | Meloxicam | 41 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | 15 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 39 | suppressed |
| Ozempic | Semaglutide | 39 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 11 |
| Methylprednisolone | Methylprednisolone | 38 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Folic Acid | Folic Acid | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Linzess | Linaclotide | 33 | 11 |
| Sucralfate | Sucralfate | 33 | 14 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 20 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Insulin Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $540.57 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, ELIQUIS, FARXIGA, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error